Regenxbio RGNX Deferred Equity Offering Costs In Accounts Payable And Accrued Expenses And Other Current Liabilities
Deferred Equity Offering Costs In Accounts Payable And Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:DeferredEquityOfferingCostsInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities.
The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regenxbio's deferred equity offering costs in accounts payable and accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regenxbio's deferred equity offering costs in accounts payable and accrued expenses and other current liabilities?
- Regenxbio (RGNX) reported deferred equity offering costs in accounts payable and accrued expenses and other current liabilities of $148K in Q1 2026.
- How has Regenxbio's deferred equity offering costs in accounts payable and accrued expenses and other current liabilities changed year-over-year?
- Regenxbio's deferred equity offering costs in accounts payable and accrued expenses and other current liabilities increased by 3.5% year-over-year, from $143K to $148K.
- What does deferred equity offering costs in accounts payable and accrued expenses and other current liabilities mean?
- This metric tracks the accrual of costs related to planned equity offerings that have been recognized in accounts payable or accrued liabilities but not yet settled in cash. It represents a short-term liability incurred to facilitate capital raising activities. Tracking this provides visibility into the company's upcoming cash requirements for financing operations.